Genetically modified stem cells for osteoporosis: a systematic review and meta-analysis of preclinical studies.

IF 2.2 3区医学 Q2 ORTHOPEDICS

BMC Musculoskeletal Disorders Pub Date : 2025-03-14 DOI:10.1186/s12891-025-08507-0

Miao Huang, Xie-Sheng Wu, Ningkun Xiao, Xinlin Huang, Peng-Fei Lin

{"title":"Genetically modified stem cells for osteoporosis: a systematic review and meta-analysis of preclinical studies.","authors":"Miao Huang, Xie-Sheng Wu, Ningkun Xiao, Xinlin Huang, Peng-Fei Lin","doi":"10.1186/s12891-025-08507-0","DOIUrl":null,"url":null,"abstract":"Objective: Our meta-analysis aims to assess the efficacy of genetically modified stem cell therapy in preclinical osteoporosis models.Methods: We executed a thorough literature search across PubMed, Embase, Web of Science, and the Cochrane Library databases from inception to September 15, 2023. We used a random-effect model for pooled analysis of the effect of genetically modified stem cell therapy on animals with osteoporosis. The primary outcomes included bone mineral density (BMD) and bone volume fraction. (BV/TV). All meta-analyses were performed employing the Cochrane Collaboration's Review Manager (version 5.3) in conjunction with Stata 15.0 statistical software.Results: A total of 2567 articles were reviewed, of which 16 articles met inclusion criteria. Of these, 13 studies evaluated the BMD and 11 studies evaluated BV/TV. Compared to the control group, genetically modified stem cell therapy was associated with significantly improved BMD (standardized mean difference [SMD] = 1.85, 95% Confidence Interval [CI]: 1.06-2.63, P < 0.001, I2 = 69%) and BV/TV (standardized mean difference [SMD] = 2.11, 95% Confidence Interval [CI]: 1.10-3.12, P < 0.001, I2 = 78%).Conclusion: Genetically modified stem cell therapy is a safe and effective method that can significantly improve the BMD and BV/TV in animal models of osteoporosis. These results provide an important basis for future translational clinical studies of genetically modified stem cells.","PeriodicalId":9189,"journal":{"name":"BMC Musculoskeletal Disorders","volume":"26 1","pages":"259"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11908096/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Musculoskeletal Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12891-025-08507-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Our meta-analysis aims to assess the efficacy of genetically modified stem cell therapy in preclinical osteoporosis models.

Methods: We executed a thorough literature search across PubMed, Embase, Web of Science, and the Cochrane Library databases from inception to September 15, 2023. We used a random-effect model for pooled analysis of the effect of genetically modified stem cell therapy on animals with osteoporosis. The primary outcomes included bone mineral density (BMD) and bone volume fraction. (BV/TV). All meta-analyses were performed employing the Cochrane Collaboration's Review Manager (version 5.3) in conjunction with Stata 15.0 statistical software.

Results: A total of 2567 articles were reviewed, of which 16 articles met inclusion criteria. Of these, 13 studies evaluated the BMD and 11 studies evaluated BV/TV. Compared to the control group, genetically modified stem cell therapy was associated with significantly improved BMD (standardized mean difference [SMD] = 1.85, 95% Confidence Interval [CI]: 1.06-2.63, P < 0.001, I² = 69%) and BV/TV (standardized mean difference [SMD] = 2.11, 95% Confidence Interval [CI]: 1.10-3.12, P < 0.001, I² = 78%).

Conclusion: Genetically modified stem cell therapy is a safe and effective method that can significantly improve the BMD and BV/TV in animal models of osteoporosis. These results provide an important basis for future translational clinical studies of genetically modified stem cells.

查看原文本刊更多论文

骨质疏松症的基因修饰干细胞：临床前研究的系统回顾和荟萃分析。

目的：我们的荟萃分析旨在评估基因修饰干细胞治疗在临床前骨质疏松症模型中的疗效。方法：我们在PubMed， Embase， Web of Science和Cochrane Library数据库中进行了从成立到2023年9月15日的全面文献检索。我们使用随机效应模型对转基因干细胞治疗对骨质疏松症动物的影响进行了汇总分析。主要结果包括骨矿物质密度（BMD）和骨体积分数。(BV /电视)。所有meta分析均采用Cochrane Collaboration的Review Manager（5.3版）和Stata 15.0统计软件进行。结果：共纳入文献2567篇，其中符合纳入标准的文献16篇。其中，13项研究评估了BMD， 11项研究评估了BV/TV。与对照组相比，转基因干细胞治疗显著改善了BMD（标准化平均差[SMD] = 1.85, 95%可信区间[CI]: 1.06-2.63, P 2 = 69%）和BV/TV（标准化平均差[SMD] = 2.11, 95%可信区间[CI]: 1.10-3.12, P 2 = 78%）。结论：基因修饰干细胞治疗是一种安全有效的方法，可显著改善骨质疏松动物模型的BMD和BV/TV。这些结果为今后基因修饰干细胞的临床转化研究提供了重要的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Musculoskeletal Disorders 医学-风湿病学

CiteScore

3.80

自引率

8.70%

发文量

1017

审稿时长

3-6 weeks

期刊介绍： BMC Musculoskeletal Disorders is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of musculoskeletal disorders, as well as related molecular genetics, pathophysiology, and epidemiology. The scope of the Journal covers research into rheumatic diseases where the primary focus relates specifically to a component(s) of the musculoskeletal system.